Icagen Company Description
Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with Johnson & Johnson subsidiary McNeil Consumer & Specialty Pharmaceuticals. Shortly thereafter Icagen announced a deal collaborating with Pfizer on the development of pain treatments.
View the Comprehensive Company Description for Icagen
The Company Description provides a historical perspective of Icagen's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Icagen's evolution in the marketplace.
